Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial

2020205 citationsJournal Articlehybrid Open Access

Authors

Chunyan Lan · Sun Yat-sen University

JingXian Shen · Sun Yat-sen University

Yin Wang · Sun Yat-sen University

Jundong Li · Sun Yat-sen University

Zhimin Liu · Sun Yat-sen University

Mian He · Sun Yat-sen University

Xinping Cao · Sun Yat-sen University

Abstract

Camrelizumab plus apatinib had promising antitumor activity and manageable toxicities in patients with advanced cervical cancer. Larger randomized controlled trials are warranted to validate our findings.

Topics & Keywords

Endometrial and Cervical Cancer Treatments Lymphoma Diagnosis and Treatment Renal cell carcinoma treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 38, Issue 34, pp. 4095-4106

DOI: 10.1200/jco.20.01920

Field-Weighted Citation Impact: 11.52